There are approximately 1 million new cases of primary hepatocellular

Size: px
Start display at page:

Download "There are approximately 1 million new cases of primary hepatocellular"

Transcription

1 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7: Liver Transplantation in Patients With Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma SHAHID M. MALIK,* PARIJAT A. GUPTE,* MICHAEL E. DE VERA, and JAWAD AHMAD* *Division of Gastroenterology, Hepatology and Nutrition and Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania See related article, Marrero JA et al, on page 110 in Gastroenterology. BACKGROUND & AIMS: The increasing incidence of hepatocellular carcinoma in the United States is only partially accounted for by hepatitis C virus (HCV) infections. The prevalence of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis (NASH) is not known; guidelines from the American Association for the Study of Liver Diseases do not recommend surveillance imaging. We sought to determine the prevalence of hepatocellular carcinoma among patients undergoing liver transplantation for NASH-related cirrhosis and their outcome after surgery, compared with controls. METHODS: We reviewed the records of adult patients with NASH cirrhosis who underwent liver transplantation by using a prospectively collected database from a single center. Data from patients with NASH cirrhosis were compared with matched controls who received transplantation for primary biliary cirrhosis/primary sclerosing cholangitis, alcoholic liver disease, or HCV. RESULTS: Seventeen of 98 patients (17%) with NASH cirrhosis were diagnosed with hepatocellular carcinoma. The mean age was 63 years, and 70% were male. Six patients were diagnosed with hepatocellular carcinoma incidentally on explant. Survival after liver transplantation was 88% after mean follow-up of 2.5 years. The number of NASH patients known to have hepatocellular carcinoma before liver transplantation was greater than the number of patients with primary biliary cirrhosis/primary sclerosing cholangitis and comparable to the number of patients with alcoholic liver disease and HCV. CONCLUSIONS: Patients with NASH cirrhosis are at risk for developing hepatocellular carcinoma; patients with NASH cirrhosis, especially men older than 50 years, should undergo surveillance imaging. Patients with NASH and hepatocellular carcinoma have good outcomes after liver transplantation. To view this article s video abstract, go to the AGA s YouTube Channel. There are approximately 1 million new cases of primary hepatocellular carcinoma (HCC) diagnosed annually worldwide. Liver cancer is the sixth most common cancer and the third most common cause of death from cancer. The majority of cases of HCC develop in patients with chronic liver disease or cirrhosis. The major risk factor for the development of HCC worldwide is infection with hepatitis B virus (HBV). 1 HCC complicating cirrhosis has a high mortality rate, unless it is detected in its early stages. Most cases do not survive a year. 2 HCC is now a leading cause of death in patients with cirrhosis. 3 5 The incidence of HCC in the United States has doubled during the last 30 years. 6 The cause of this increase is incompletely understood. The increasing incidence in the United States has been partially attributed to hepatitis C virus (HCV)- associated cirrhosis, with HBV and alcoholic liver disease (ALD) playing a smaller role. 7 Up to one half of HCC cases in the United States, however, are idiopathic, suggesting that other risk factors are responsible for this increase. 8 Recent studies have suggested that the epidemic rise in obesity and diabetes mellitus (DM) could account for at least a portion of these idiopathic cases Although it is unproved, some experts hypothesize that the relationship of obesity and DM to HCC is mediated through the development of nonalcoholic steatohepatitis (NASH). 11 As the incidence of obesity, DM, and other features of metabolic syndrome increases, so too does the incidence of NASH. It is estimated that nearly 10 million Americans have NASH, making it the most common cause of chronic liver disease in the United States. 12 NASH cirrhosis is likely to become a leading indication for liver transplantation (LT) in the near future. 13 Although NASH is known to progress to end-stage liver disease, little is known about the incidence of HCC in patients with NASH cirrhosis. There is growing evidence, however, indicating that HCC should be considered in the natural history of progressive NASH. The first reported case of NASH-related HCC was published in Since then, several case reports and case series have documented the occurrence of HCC in patients with NASH The American Association for the Study of Liver Disease (AASLD) currently recommends screening and surveillance for HCC in high-risk groups, including hepatitis B carriers and Abbreviations used in this paper: AASLD, American Association for the Study of Liver Diseases; AFP, alpha-fetoprotein; ALD, alcoholic liver disease; BMI, body mass index; CIT, cold ischemic time; CTP, Child- Turcotte-Pugh; CT, computed tomography; DM, diabetes mellitus; FAL, fractional allelic loss; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HTN, hypertension; LOH, loss of heterozygosity; LOS, length of stay; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; MRI, magnetic resonance imaging; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; US, ultrasound; WIT, warm ischemic time by the AGA Institute /09/$36.00 doi: /j.cgh

2 July 2009 LIVER TRANSPLANT FOR NASH HCC 801 cirrhosis caused by hepatitis C, alcohol, hemochromatosis, and primary biliary cirrhosis (PBC). Although the guidelines acknowledge that cirrhosis from other diseases (NASH, alpha 1 - antitrypsin deficiency, and autoimmune hepatitis) puts patients at an increased risk for the development of HCC, they state that in these patients no recommendations for or against surveillance can be made because of a lack of data (that) precludes an assessment of whether surveillance would be beneficial. 21 The aims of this study were 2-fold: (1) to determine the incidence of HCC in patients who underwent LT for a diagnosis of NASH cirrhosis compared with the other most common indications for LT in the United States and (2) to determine the outcome of patients with HCC and NASH cirrhosis undergoing LT. Materials and Methods We retrospectively reviewed the records of all adult patients undergoing LT for a diagnosis of NASH cirrhosis by using a prospectively collected database at a single center. Patients were considered to have a diagnosis of NASH cirrhosis on the basis of histopathologic findings and if they fulfilled the following criteria: absence of alcohol history, exclusion of other forms of chronic liver disease, on the basis of history, laboratory testing, histology, and absence of potential exposures to hepatotoxins or medications associated with hepatic steatosis. All patients underwent extensive serologic testing, including testing for hepatitis B (hepatitis B surface antibody, surface antigen, and core antibody), hepatitis C (hepatitis C second-generation enzyme-linked immunosorbent assay, HCV RNA), hemochromatosis (serum iron, % saturation, total iron binding capacity, ferritin, and HFE genetic testing if indicated), Wilson disease (ceruloplasmin levels), alpha 1 -antitrypsin deficiency (alpha 1 -antitrypsin levels and phenotype), autoimmune hepatitis (antinuclear antibody titers, anti smooth muscle antibody titers, anti liver kidney microsomal antibody titers, and quantitative immunoglobulin levels), and PBC (antimitochondrial antibody titers). All pre-lt imaging (ultrasound [US] and either triphasic computed tomography [CT] scan or magnetic resonance imaging [MRI]) reports were reviewed. All explants were examined by experienced hepatopathologists. All explant biopsy reports and available biopsy reports before transplant were reviewed to ensure findings consistent with NASH or NASH cirrhosis. Histologic criteria for NASH included macrovesicular hepatic steatosis, Mallory s hyaline, ballooning degeneration, scattered predominantly neutrophilic inflammation, and pericentral and perisinusoidal fibrosis. 22 Demographic data collected included recipient characteristics (age, sex, race, body mass index [BMI], history of alcohol or illicit drug use, medical history, laboratory data, Model for End-Stage Liver Disease [MELD] score, Child-Turcotte-Pugh [CTP] score, and the number of patients on dialysis or intubated before transplant), patient survival in days, retransplantation, and cause of death. Donor characteristics included age, sex, race, BMI, cause of death, and percent steatosis on biopsy (when available). Surgical cold ischemia times (CITs) and warm ischemia times (WITs), length of operation, and total transfusion requirement during the operation were also noted. Outcome after LT was determined by (1) patient survival, defined as short-term (30 days) and long-term (1, 3, and 5 years), and (2) length of stay (LOS) after transplant, defined as number of hospital days (intensive care unit or otherwise) in patients who were eventually discharged from the hospital to home, rehabilitation, or nursing facility. Incidental HCC was defined as a cancer found only on pathologic evaluation of the explanted native liver, without evidence on pre-lt imaging. Although pretransplant alphafetoprotein (AFP) was reviewed on all patients, elevated levels were not considered diagnostic of HCC before transplant. This is in concordance with previously published data on the definition of incidental HCC. 23,24 Explant reports from all patients with HCC were reviewed. The number of tumors, largest tumor size, tumor differentiation, evidence of microscopic vascular invasion, pathologic TNM classification, pathologic staging, and genetic analysis/ loss of heterozygosity (LOH) were noted. HCC for topographic genotyping was performed on 9 of 17 (52.9%) patients. In these patients, microdissected targets were performed on HCC lesions to determine allelic imbalance or LOH. The fractional allelic loss (FAL) rate was defined as the fraction of mutated markers divided by the total number of informative markers. On the basis of previously published data, an FAL of 0.3 was supportive of indolent behavior, and an FAL 0.3 indicated the capacity for aggressive behavior. 25 Patients with HCC (both known and incidental) are followed at our institution for recurrence with either CT or MRI of the chest, abdomen, and pelvis every 3 months for the first year, every 6 months for the next year, and then annually. Comparison Groups Patients with NASH cirrhosis were compared in a 1:2 ratio with patients in each of 3 control groups (total 588 patients) who were transplanted for cholestatic liver disease (PBC/primary sclerosing cholangitis [PSC]), ALD, or HCV. The control groups were matched (in order of priority) for age, sex, MELD score, and year of transplant. Patients with NASH-related HCC were also compared with all patients transplanted at our center with a diagnosis of HCC during the last 15 years with etiologies other than NASH. Statistical Analysis Continuous variables were compared by using Student t test. Categorical variables were compared by using 2 test. Survival after LT was calculated by using the Kaplan Meier method and compared by using the log-rank test. Data are expressed as means. All analyses were performed by using Stata 8.0 (Statacorp, College Station, TX). The study was approved by the University of Pittsburgh Institutional Review Board. Results Of 2012 adult patients who underwent LT at our center from July 6, 1997 to June 31, 2008, we identified 143 patients with a diagnosis of NASH cirrhosis. After review, 45 patients were eliminated for the following reasons: cryptogenic cirrhosis (n 12), evidence of alpha 1 -antitrypsin deficiency (n 7), autoimmune hepatitis (n 5), alcohol use (n 5), hemochromatosis (n 4), HCV (n 3), HCV/ALD (n 2), Wilson disease (n 2), methotrexate-induced liver injury (n 2), possible acetaminophen toxicity (n 1), fulminant hepatic failure (n 1), and HBV/ALD (n 1), leaving 98 patients (4.8%

3 802 MALIK ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 7, No. 7 Table 2. Donor, Surgical, and Mortality Data of 81 Patients With NASH Cirrhosis Undergoing LT Compared With 17 With NASH-Related HCC NASH (n 81) NASH HCC (n 17) P value Age (y) Sex (male) 42 (51.9%) 11 (64.7%).24 Race (white) 69 (85.2%) 15 (88.2%).55 BMI (kg/m 2 ) Live donor 10 (12.0%) 3 (17.6%).40 CIT (min) WIT (min) Operating room time (min) PRBC transfusions during LT (units) Figure 1. Flow diagram of 2012 adult LT recipients showing criteria used for diagnosis of NASH cirrhosis. of 2021 total adult LTs) transplanted with a primary diagnosis of NASH cirrhosis (Figure 1). Most of the 12 patients with cryptogenic cirrhosis had clinical features consistent with NASH, but a diagnosis of NASH could not be confirmed by histology (likely burnt out NASH ). We elected not to include these 12 patients among our NASH cohort. Seventy-one of 98 patients had pretransplant biopsies consistent with a diagnosis of NASH. The remaining 27 patients included in the cohort had explant biopsy findings diagnostic for NASH. Of the 71 patients who had pre-lt biopsies diagnosing NASH, 49 had explant findings consistent with NASH, Table 1. Baseline Recipient Characteristics and Mortality Data of 81 Patients With NASH Cirrhosis Undergoing LT Compared With 17 Patients With NASH Cirrhosis and HCC NASH (n 81) NASH HCC (n 17) P value Age (y) Range Median Sex (male) 32 (39.5%) 12 (70.6%).02 Race (white) 79 (97.5%) 16 (94.1%).44 BMI (kg/m 2 ) BMI 30 (kg/m 2 ) 49 (60.5%) 12 (70.6%).31 DM 59 (72.8%) 12 (70.6%).53 HTN 41 (50.6%) 8 (47.1%).50 DM HTN 36 (44.4%) 6 (35.3%).34 Metabolic syndrome 49 (60.5%) 12 (70.6%).31 CTP score Calculated MELD score Intubated 6 (7.4%) 0.31 Dialysis 8 (9.9%) 3 (17.6).29 Intubated dialysis 3 (3.7%) Day mortality 8 (9.9%) 2 (11.1%).55 1-Year mortality 16 (19.8%) 2 (11.1%).35 3-Year mortality 23 (28.4%) 2 (11.1%).13 5-Year mortality 25 (30.9%) 2 (11.1%).09 LOS (days) PRBC, packed red blood cells. and 22 (31%) had developed significant fibrosis or complete cirrhosis with little remaining diagnostic features of NASH (Figure 1). Baseline characteristics of all patients and donors (98 NASH and 588 controls) and their outcomes after LT have been documented elsewhere. 26 Of the 98 NASH patients, 17 (17.3%) were diagnosed with HCC. The characteristics of recipients and mortality data with HCC and those without HCC are summarized in Table 1. Donor and surgical characteristics are summarized in Table 2. The mean age of patients with HCC was years. Of the 17 patients, 16 were white, and 1 was Asian. The mean BMI was 33.0 kg/m 2. Only 1 patient had a BMI 29 kg/m 2 ; twelve of the 17 patients were obese (BMI 30 kg/m 2 ). Seventy percent of patients carried a diagnosis of DM before transplant, and 47% had hypertension (HTN). Twelve of the 17 patients with HCC and NASH cirrhosis met criteria for metabolic syndrome (with criteria defined by the American Association of Clinical Endocrinologists 27 ). There were significantly more men in the HCC cohort (70.6% versus 39.5%, P.02). Tumor characteristics are outlined in Table 3. Eleven patients were known to have HCC before LT. Six of these patients were treated before LT with chemoembolization. All 17 patients had histologic evidence of cirrhosis. Six patients had HCC discovered incidentally on examination of the explant. All but one of the incidental tumors were less than 2.5 cm (9 tumors, mean size 1.7 cm). One patient with an incidental tumor discovered on explant had an AFP of 882 ng/ml. The explant revealed a 5-cm tumor. Although the preoperative CT scan read the corresponding lesion as an area of fatty infiltration, because of the high suspicion for malignancy, the patient was listed with a MELD upgrade. One patient (case 14) was diagnosed with a mass on pre-lt imaging (with normal AFP and CA19-9) and was being treated with chemoembolization. Explant analysis of the tumor confirmed the presence of a mixed HCC and cholangiocarcinoma. Another patient (case 16) was diagnosed with a 4.5-cm welldifferentiated HCC. The patient was treated with chemoembolization and 4 months after diagnosis underwent LT. Analysis of the explanted liver revealed no evidence of viable tumor. Two patients (cases 4 and 12) would have been considered outside of Milan criteria on the basis of explant findings. Case 4 underwent an MRI before LT that revealed 3 lesions, the

4 July 2009 LIVER TRANSPLANT FOR NASH HCC 803 Table 3. Tumor Characteristics of 17 NASH Patients With HCC Undergoing LT Case Age (y) Sex Race BMI (kg/m 2 ) DM HTN K/I AFP (ng/ml) Diff No. of tumors Largest tumor explant (cm) Microscopic vascular invasion TNM Pathologic stage LOH 1 69 M W N N I 4 Mod N T2NxMx II NP 2 68 M W Y Y K 1151 Mod Y T2NxMx II NP 3 56 M W Y Y I 882 Mod 1 5 Y T2NxMx II NP 4 72 F W Y N K 4 Well N T3N0Mx IIIA 10% 5 64 M W N N K 2 Mod 2 3 Y T3N0Mx IIIA NP 6 65 M W Y N K 137 Well 1 8 N T3N0Mx IIIA NP 7 59 M W N N I 8 Mod N T1N0Mx I 13% 8 57 F W Y N I 4 Well N T2NxMx II NP 9 63 F W N Y I 2 Well N T2NxMx II NP M A Y Y K 5 Mod 1 4 N T1N0Mx I 40% M W Y Y I 2 Mod N T2NxMx II 22% M W Y N K 10 Mod 10 4 Y T2NxMx II 38% M W Y Y K 2 Poor Y T2N0Mx II 77% M W Y Y K 3 Mod N T2N0Mx II 15% M W Y N K 6 Mod N T2NxMx II 47% F W N Y K 13 Well N T1N0Mx I NP F W Y N K 12 Mod 1 4 N T1N0Mx I 19% W, white; A, Asian; N, no; Y, yes; K, known; I, incidental; Diff, tumor differentiation; Mod, moderately differentiated; Well, well-differentiated; Poor, poorly differentiated; NP, not performed. largest of which was 3 cm, and so the patient was within Milan criteria before listing. Case 12 was a patient with biopsy-proven HCC. He underwent a CT scan 3 months before LT that revealed 8 lesions; the largest was 4 cm. The patient was treated with 1 round of chemoembolization before transplant, with significant improvement on the basis of follow-up imaging. Because he was outside Milan criteria, he and his family were counseled and were agreeable to live donor transplantation. There was no difference in 5-year survival between patients transplanted for NASH cirrhosis with and without HCC (Figure 2). Patient survival was 88% at a mean follow-up of 2.5 years (range, 3 months 6.5 years). One death was immediately postoperative and cardiac-related. The other death occurred 6 months after LT and was related to infection. The 15 remaining patients have been followed after LT with serial imaging. One patient (case 13) was noted to have pulmonary nodules on Figure 2. Kaplan Meier survival curve for 81 patients transplanted for NASH cirrhosis versus 17 patients transplanted for NASH HCC. P.14 by log-rank (analysis time in days). imaging 6 months after LT. Biopsy of the nodules showed metastatic HCC. Despite being started on sorafenib, most recent imaging showed brain lesions concerning for metastatic disease. This was the only patient who had poorly differentiated carcinoma on the explant and had the most aggressive biology of all patients who underwent genetic analysis. There was no evidence of recurrent disease on surveillance imaging in the remaining patients. Three of the 17 patients with HCC received live donor transplants. Five of the 11 patients with known HCC were given MELD upgrades, as was the patient with an elevated AFP of 882 ng/ml. Table 4 details the breakdown of known, incidental, and total HCCs between the 4 groups. The total number of primary cancers (known incidental) in the NASH HCC cohort was higher when compared with those with PBC/PSC and comparable to the ALD group. Nearly 28% of patients with HCV had a diagnosis of HCC at the time of LT, which was the highest among the 4 groups. When comparing the 17 patients with HCC and NASH with all patients who underwent transplantation at our institution during the last 15 years with a diagnosis of HCC (n 430: 32% HCV, 23% ALD, 12% HBV, 8% cryptogenic, 7% HCV/ALD, 5% PBC/PSC, 3% autoimmune, 2% hemochromatosis, 1% alpha 1 - antitrypsin deficiency, 3% other), NASH patients with HCC were older and heavier and had a higher incidence of pre-lt DM and HTN (Table 5). There was no difference in the total number of HCCs at the time of LT between these 2 groups. Five-year survival after LT was comparable between the 2 groups (Figure 3). Because a large percentage of cryptogenic cirrhosis is likely to be burnt out NASH, the analysis was also performed by including patients with cryptogenic cirrhosis within the NASH cohort, and outcomes were unchanged. Discussion Because the incidence of HCC in cirrhosis caused by NASH is unknown, it is not possible to assess whether surveil-

5 804 MALIK ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 7, No. 7 Table 4. Number of Known, Incidental, and Total HCCs at the Time of LT for NASH Compared With PBC/PSC, ALD, and HCV Known Incidental Total NASH (n 98) 11 (11.2%) 6 (6.1%) 17 (17.3%) PBC/PSC (n 198), P value 3 (1.5%), (5.6%), (7.1%),.01 ALD (n 198), P value 18 (9.1%),.35 9 (4.5%), (13.6%),.25 HCV (n 198), P value 26 (13.1%), (14.6%), (27.8%),.03 NOTE. P value comparison vs NASH cohort. lance might be effective or cost-efficient. Because of this, the most recent AASLD practice guidelines cannot give recommendations on whether this group should be surveyed for HCC. This study demonstrated that patients with NASH cirrhosis evaluated and then undergoing LT have a 17.3% incidence of HCC, suggesting that surveillance imaging for HCC is required, particularly because one third of the cancers were only discovered in the explanted liver. The incidence of known primary liver cancers in patients with NASH cirrhosis was significantly higher when compared with those with PBC/PSC and comparable to patients with HCV cirrhosis and ALD, all groups in which the current guidelines recommend routine surveillance. Before the present study, fewer than 40 cases of HCC associated with NASH had been reported in the literature (excluding patients with cryptogenic cirrhosis who likely had NASH cirrhosis in retrospect). Interestingly, the majority (89%) of previously described cases were reported in Japan. The 17 patients described here were younger but had a similar sex distribution and similar features of metabolic syndrome. The younger age in our cohort likely reflects a selection bias in the listing of transplant recipients. Despite the multiple medical comorbidities, patients with NASH and HCC had good outcomes after LT. Patient survival at a mean follow-up of approximately 2.5 years was an excellent 88%. These results are very good, considering the 3-year survival rate of small, untreated HCC in patients with cirrhosis is only 25%. 28 Five-year survival after LT was comparable to those Table 5. Recipient Characteristics of 430 Patients Undergoing LT With HCC (Excluding NASH) Compared With 17 Patients With NASH- Related HCC HCC non-nash (n 430) NASH HCC (n 17) P value Age (y) Range Median Sex (male) 339 (78.8%) 12 (70.6%).12 Black 28 (6.5%) 0.01 BMI (kg/m 2 ) BMI 30 (kg/m 2 ) 115 (26.7%) 12 (70.6%).0001 DM 91 (21.2%) 12 (70.6%).0001 HTN 87 (20.2%) 8 (47.1%).01 DM HTN 41 (9.5%) 6 (35.3%).01 AFP (ng/ml) AFP % (26.0%) 3 (17.6%).32 Incidence of total 430/2514 (17.1%) 17/98 (17.3%).52 HCCs Known 160 (6.3%) 11 (11.2%).05 Incidental 270 (10.7%) 6 (6.1%).09 without HCC. Only 1 patient was found to have recurrence of disease. The 2 deaths among the 17 patients were within 1 year of transplant and not related to recurrence of cancer. As evidenced by the current study and previous studies, a significant number of patients with NASH have features of metabolic syndrome. Not surprisingly, patients with NASH cirrhosis were significantly more obese and had a higher incidence of pre-lt DM and HTN, compared with controls and with all non-nash patients with HCC transplanted at our center during the last 15 years. Obesity has been confirmed to lead to an increased risk for HCC in several studies, as has diabetes However, in the current study, although patients with NASH were significantly heavier and had a higher incidence of pre-lt DM and HTN versus the 3 control groups (and versus all patients transplanted with HCC), there was no statistical difference in these 3 variables among NASH patients with and without HCC, perhaps indicating that factors independent of metabolic syndrome might play a role in the neoplastic process. The mechanism of carcinogenesis in patients with NASH is not understood. Studies performed on genetically obese, insulin-resistant ob/ob mice might provide some insight into factors involved in the development of liver cancer in NASH. Lipid peroxidation, free radical oxidative stress, and hepatocyte proliferation in the setting of insulin resistance are hypothesized to contribute to the process of initiating malignant transformation in the setting of what was previously benign steatosis. 34,35 Both increasing age and male sex are known risk factors for HCC in patients with cirrhosis Patients with NASH cirrho- Figure 3. Kaplan Meier survival curve for 430 patients undergoing LT with HCC (non-nash related) versus 17 patients transplanted for NASH HCC. P.15 by log-rank (analysis time in days).

6 July 2009 LIVER TRANSPLANT FOR NASH HCC 805 sis and HCC were on average 5 years older than all other patients transplanted for HCC at our institution. This might indicate either that the onset of NASH occurs later in life, or that decompensation and malignant degeneration occur more slowly in patients with NASH as compared with other forms of chronic liver disease. Although 55% of our NASH cohort was female, only 5 of the 17 patients with HCC were women. This is in concordance with known data that men are far more likely to develop HCC than women. 37,38 The reported incidence of incidental HCC is highly variable, ranging from less than 10% 24 to as high as 60%. 39 In our study the incidence (from a total of 686 patients) was 8.0%. The incidence of incidental carcinoma from all patients with HCC (n 430) at our center during the last 15 years was 11.9%. There were several limitations to the current study. Given the retrospective nature of the study, it was not always possible to determine exactly when patients were diagnosed with NASH cirrhosis and in what time frame they developed HCC. There is a selection bias inherent in listing patients for LT, and so our data do not give a true reflection of the incidence of HCC in patients with NASH, because patients who were very old or obese or who had too large or numerous tumors would not have been listed. Another limitation is the relatively short mean follow-up of 2.5 years in our cohort. However, all recent studies examining recurrent HCC after LT have found that most patients who will experience recurrence will do so within the first year, and nearly all who develop recurrence will declare themselves within the first 3 years after transplant In conclusion, the current study confirms that HCC is part of the natural history of patients with NASH cirrhosis listed and undergoing LT, with the number of known cancers greater than that seen with cholestatic liver disease and comparable to ALD and HCV. The current findings suggest that surveillance imaging for HCC in patients with NASH cirrhosis might be warranted. Age and sex likely play a role in the incidence, and, hence, extra vigilance should be paid to men with NASH cirrhosis older than the age of 50. Furthermore, if detected early, the outcome after LT for patients with NASH and HCC is comparable to other causes of HCC. Supplementary Data Note: To access the supplementary material accompanying this article, visit the online version of Clinical Gastroenterology and Hepatology at and at doi: /j.cgh References 1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, CA Cancer J Clin 2005;55: Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5 S Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000;47: Benvegnu L, Gios M, Boccato S, et al. Natural history of compensated viral cirrhosis: a prospective study on the incidence of hierarchy of major complications. Gut 2004;53: Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17 year cohort study of 214 patients. Hepatology 2006;43: El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340: El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160: Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005;54: Regimbeau JM, Colombat M, Mognol P, et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004;10:S69 S El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systemic review of the epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4: Caldwell SH, Crespo DM, Kang HS, et al. Obesity and hepatocellular carcinoma. Gastroenterology 2004;127:S97 S Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2: Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11: Cotrim HP, Parana R, Braga E, et al. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am J Gastroenterol 2000;95: Shimada M, Hashimoto E, Taniai M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002;37: Mori S, Yamasaki T, Sakaida I, et al. Hepatocellular carcinoma with nonalcoholic steatohepatitis. J Gastoenterol 2004;39: Hashimoto E, Yatsuji S, Kaneda H, et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 2005;33: Ichikawa T, Yanagi K, Motoyoshi Y, et al. Two cases of nonalcoholic steatohepatitis with development of hepatocellular carcinoma without cirrhosis. J Gastroenterol Hepatol 2006;21: Hashizume H, Sato K, Takagi H, et al. Primary liver cancers with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2007; 19: Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42: Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21: Chui AK, Rao AR, McCaughan GW, et al. Liver transplantation for hepatocellular carcinoma in cirrhotic patients. Aust N Z J Surg 1999;69: Choi SH, Lee HH, Lee DS, et al. Clinicopathological features of incidental hepatocellular carcinoma in liver transplantation. Transplant Proc 2004;36: Finkelstein SD, Marsh W, Demetris AJ, et al. Microdissectionbased allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology 2003;37: Malik SM, de Vera M, Fontes P, et al. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 2009;9: Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus on the insulin resistance syndrome. Diabetes Care 2003;26: Barbara L, Benzi G, Giaini S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992;16: Samanic C, Gridley G, Chow WH, et al. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 2004;15: Moller H, Mellemgaard A, Lindvig K, et al. Obesity and cancer

7 806 MALIK ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 7, No. 7 risk: a Danish record-linkage study. Eur J Cancer 1994;30: Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001; 12: Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histological findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 2005;23: Ioannou GN, Splan MF, Weiss NS, et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007;5: Yang S, Lin HZ, Hwang J, et al. Hepatic hyperplasia in noncirrhotic fatty liver: is obesity-related hepatic steatosis a premalignant condition? Cancer Res 2001;61: Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007;11: del Olmo JA, Serra MA, Rodriguez F, et al. Incidence and risk factors for hepatocellular carcinoma in 967 patients with cirrhosis. J Cancer Res Clin Oncol 1998;124: Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127:S35 S Zaman SN, Melia WM, Johnson RD, et al. Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1985;1: Caroli-Bottino A, Nascimento CM, Basto S, et al. Hepatocellular carcinoma: incidental finding in cirrhotic explants livers. Transplant Proc 2005;37: Marsh JW, Dvorchik I, Subotin M, et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology 1997;26: Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004;10: Chan EY, Larson AM, Fix OK, et al. Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transpl 2008;14: Reprint requests Address requests for reprints to: Shahid M. Malik, MD, Division of Gastroenterology, Hepatology and Nutrition, Suite 900, 3471 Fifth Avenue, Pittsburgh, Pennsylvania maliks@upmc.edu; fax: (412) Conflicts of interest The authors disclose no conflicts.

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views

More information

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis

More information

Hepatocellular Carcinoma in Qatar

Hepatocellular Carcinoma in Qatar Hepatocellular Carcinoma in Qatar K. I. Rasul 1, S. H. Al-Azawi 1, P. Chandra 2 1 NCCCR, 2 Medical Research Centre, Hamad Medical Corporation, Doha, Qatar Abstract Objective The main aim of this study

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C

More information

Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States

Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States GASTROENTEROLOGY 2011;141:1249 1253 Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States MICHAEL R. CHARLTON,* JUSTIN M. BURNS, RACHEL A. PEDERSEN, KYMBERLY

More information

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

The impact of the treatment of HCV in developing Hepatocellular Carcinoma The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University

More information

Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995

Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Steven H. Belle, Kimberly C. Beringer, and Katherine M. Detre T he Scientific Liver Transplant Registry (LTR) was established

More information

Hepatocellular Carcinoma: Can We Slow the Rising Incidence?

Hepatocellular Carcinoma: Can We Slow the Rising Incidence? Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline

More information

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%

More information

Hepatocellular Carcinoma Surveillance

Hepatocellular Carcinoma Surveillance Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated

More information

Screening for HCCwho,

Screening for HCCwho, Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology

More information

Surveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice

Surveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline

More information

EVALUATION OF ABNORMAL LIVER TESTS

EVALUATION OF ABNORMAL LIVER TESTS EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical

More information

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology

More information

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas Jose D Sollano, MD Professor of Medicine Manila, Philippines International Variation in Age-Standardized Liver Cancer Incidence Rates in Both Sexes, 2008 Global Age-Standardized Liver Cancer Incidence

More information

What Is the Real Gain After Liver Transplantation?

What Is the Real Gain After Liver Transplantation? LIVER TRANSPLANTATION 15:S1-S5, 9 AASLD/ILTS SYLLABUS What Is the Real Gain After Liver Transplantation? James Neuberger Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, United Kingdom;

More information

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology

More information

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty

More information

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer

More information

Tumor incidence varies significantly, depending on geographical location.

Tumor incidence varies significantly, depending on geographical location. Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.

More information

Hepatocellular Carcinoma (HCC): Burden of Disease

Hepatocellular Carcinoma (HCC): Burden of Disease Hepatocellular Carcinoma (HCC): Burden of Disease Blaire E Burman, MD VM Hepatology Hepatocellular Carcinoma (HCC) Primary HCCs most often arise in the setting of chronic inflammation, liver damage, and

More information

Clinical Significance of Elevated -Fetoprotein in Adults and Children

Clinical Significance of Elevated -Fetoprotein in Adults and Children , pp. 1709 1713 Clinical Significance of Elevated -Fetoprotein in Adults and Children RANDEEP KASHYAP,* ASHOK JAIN, MD,* MICHAEL NALESNIK, BRIAN CARR,* JACKIE BARNES,* HUGO E. VARGAS, JORGE RAKELA, and

More information

Recurrent Disease Following Liver Transplantation for Nonalcoholic Steatohepatitis Cirrhosis

Recurrent Disease Following Liver Transplantation for Nonalcoholic Steatohepatitis Cirrhosis LIVER TRAPLANTATION 15:1843-1851, 2009 ORIGINAL ARTICLE Recurrent Disease Following Liver Transplantation for Nonalcoholic Steatohepatitis Cirrhosis Shahid M. Malik, 1 Michael E. devera, 2 Paulo Fontes,

More information

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer

More information

Hepatocellular Carcinoma: Epidemiology and Screening

Hepatocellular Carcinoma: Epidemiology and Screening Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman

More information

Transplant Hepatology

Transplant Hepatology Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified

More information

PREVALENCE OF NAFLD & NASH

PREVALENCE OF NAFLD & NASH - - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)

More information

Liver Transplantation Evaluation: Objectives

Liver Transplantation Evaluation: Objectives Liver Transplantation Evaluation: Essential Work-Up Curtis K. Argo, MD, MS VGS/ACG Regional Postgraduate Course Williamsburg, VA September 13, 2015 Objectives Discuss determining readiness for transplantation

More information

Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants

Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:700 704 Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants JACQUELINE G. O LEARY, CARMEN

More information

NIH Public Access Author Manuscript J Surg Res. Author manuscript; available in PMC 2011 May 18.

NIH Public Access Author Manuscript J Surg Res. Author manuscript; available in PMC 2011 May 18. NIH Public Access Author Manuscript Published in final edited form as: J Surg Res. 2011 April ; 166(2): 189 193. doi:10.1016/j.jss.2010.04.036. Hepatocellular Carcinoma Survival in Uninsured and Underinsured

More information

RESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment

RESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment DOI:10.22034/APJCP.2017.18.6.1697 RESEARCH ARTICLE Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment Alan Chuncharunee 1,

More information

Hepatocellular Carcinoma. Markus Heim Basel

Hepatocellular Carcinoma. Markus Heim Basel Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749

More information

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age

More information

6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare

6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare 6 Riunione Monotematica A.I.S.F. 2015 NASH malattia epatica, oncologica e cardiovascolare Modena, 9 ottobre 2015 Massimo Colombo NAFLD e HCC: caratteristiche distintive Chairman Department of Liver, Kidney,

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

HEPATOCELLULAR CARCINOMA: AN OVERVIEW

HEPATOCELLULAR CARCINOMA: AN OVERVIEW HEPATOCELLULAR CARCINOMA: AN OVERVIEW John K. Olynyk Head, Department of Gastroenterology & Hepatology Fiona Stanley Fremantle Hospital Group Dean of Research, Edith Cowan University RISING MORTALITY OF

More information

FATTY LIVER DISEASE (NAFLD) (NASH) A GROWING

FATTY LIVER DISEASE (NAFLD) (NASH) A GROWING NON ALCOHOLIC FATTY LIVER DISEASE () & NON ALCOHOLIC S T E ATO H E PAT I T I S () ADDRESSING A GROWING SILENT EPIDEMIC Prevalence of & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams

More information

Liver resection for HCC

Liver resection for HCC 8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the

More information

Surveillance for Hepatocellular Carcinoma

Surveillance for Hepatocellular Carcinoma Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April

More information

Viral hepatitis and Hepatocellular Carcinoma

Viral hepatitis and Hepatocellular Carcinoma Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline

More information

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to

More information

Survival of Liver Transplant Recipients With Hemochromatosis in the United States

Survival of Liver Transplant Recipients With Hemochromatosis in the United States GASTROENTEROLOGY 2007;133:489 495 Survival of Liver Transplant Recipients With Hemochromatosis in the United States LEI YU*, and GEORGE N. IOANNOU*, *Division of Gastroenterology, Department of Medicine

More information

Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview.

Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview. Review Med Ultrason 2014, Vol. 16, no. 2, 139-144 DOI: Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview. Mirela Dănilă, Ioan Sporea Gastroenterology

More information

Management of HepatoCellular Carcinoma

Management of HepatoCellular Carcinoma 9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma

More information

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk Fatty liver disease Is there fatty

More information

Liver transplantation: Hepatocellular carcinoma

Liver transplantation: Hepatocellular carcinoma Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona

More information

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France NASH : a severe hepatic

More information

Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Fatty Liver Disease (NAFLD) HEPATO-PANCREATO-BILIARY STOMACH CANCER PROGRAM Non-Alcoholic Fatty Liver Disease (NAFLD) Steatosis and Non-Alcoholic Steatohepatitis (NASH) Management Recommendations UCSF Fresno Department of Surgery

More information

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion

More information

Liver Pathology in the 0bese

Liver Pathology in the 0bese Liver Pathology in the 0bese Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Ludwig et al. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

More information

Improving Access to Quality Medical Care Webinar Series

Improving Access to Quality Medical Care Webinar Series Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX

More information

Update on HIV-HCV Epidemiology and Natural History

Update on HIV-HCV Epidemiology and Natural History Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,

More information

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none

More information

Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC) Title Slide Hepatocellular Carcinoma (HCC) Professor Muhammad Umar MBBS, MCPS, FCPS (PAK), FACG (USA), FRCP (L), FRCP (G), ASGE-M(USA), AGAF (USA) Chair & Professor of Medicine Rawalpindi Medical College

More information

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon

More information

The future of liver transplantation for viral hepatitis

The future of liver transplantation for viral hepatitis The future of liver transplantation for viral hepatitis François Durand Hepatology & Liver Intensive Care Hospital Beaujon, Clichy University Paris Diderot France Liver transplantation in France 2013:

More information

Is exposure to Agent Orange a risk factor for hepatocellular cancer? A single-center retrospective study in the U.S. veteran population

Is exposure to Agent Orange a risk factor for hepatocellular cancer? A single-center retrospective study in the U.S. veteran population Original Article Is exposure to Agent Orange a risk factor for hepatocellular cancer? A single-center retrospective study in the U.S. veteran population Padmini Krishnamurthy, Nyla Hazratjee, Dan Opris,

More information

Steatohepatitic Hepatocellular Carcinoma, a Morphologic Indicator of Associated Metabolic Risk Factors

Steatohepatitic Hepatocellular Carcinoma, a Morphologic Indicator of Associated Metabolic Risk Factors Steatohepatitic Hepatocellular Carcinoma, a Morphologic Indicator of Associated Metabolic Risk Factors A Study From India Deepali Jain, MD, DNB; Nabeen C. Nayak, MD, FRCPath; Vinay Kumaran, MS, MCh; Sanjiv

More information

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate

More information

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:989 994 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Level of -Fetoprotein Predicts Mortality Among Patients With Hepatitis C Related Hepatocellular

More information

Steatosi epatica ed HCV

Steatosi epatica ed HCV Steatosi epatica ed HCV Malattie delle vie biliari ed Epatologia Rho, Auditorium Padri Oblati, 11 Novembre 2006 Piero L. Almasio Università di Palermo HISTOPATHOLOGY Steatosis and accelerated fibrogenesis:

More information

Chronic liver failure Assessment for liver transplantation

Chronic liver failure Assessment for liver transplantation Chronic liver failure Assessment for liver transplantation Liver Transplantation Dealing with the organ shortage Timing of listing must reflect length on waiting list Ethical issues Justice, equity, utility

More information

Hepatology for the Nonhepatologist

Hepatology for the Nonhepatologist Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning

More information

Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology

Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology Nonalcoholic steatohepatitis and Fatty Liver Disease Liver manifestations of the obesity epidemic Changes

More information

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk @robdgol FATTY LIVER DISEASE Brunt

More information

Screening for hepatocellular carcinoma (HCC) is controversial.

Screening for hepatocellular carcinoma (HCC) is controversial. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:508 512 Screening for Hepatocellular Carcinoma Among Veterans With Hepatitis C on Disease Stage, Treatment Received, and Survival LUCI K. LEYKUM,* HASHEM

More information

Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic

Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics

More information

Workup of a Solid Liver Lesion

Workup of a Solid Liver Lesion Workup of a Solid Liver Lesion Joseph B. Cofer MD FACS Chief Quality Officer Erlanger Health System Affiliate Professor of Surgery UTHSC-Chattanooga I have no financial or other relationships with any

More information

STOP Hepatocellular Carcinoma

STOP Hepatocellular Carcinoma STOP Hepatocellular Carcinoma Laura Tenner MD MPH, Amit G. Singal MD MS, Mamta Jain MD, Barbara Turner MD, Barbara Riske MS ReACH Center and Dept of Medicine UT Health San Antonio Dept of Medicine UT Southwestern

More information

Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant

Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant ORIGINAL ARTICLE July-August, Vol. 15 No. 4, 2016: 545-549 545 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian Association

More information

New insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College

New insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College New insights into fatty liver disease Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Prevalence of NASH Global prevalence of NAFLD is 25% with highest prevalence in the Middle

More information

Most hepatocellular carcinoma (HCC) arises on a background

Most hepatocellular carcinoma (HCC) arises on a background Does Nonalcoholic Fatty Liver Disease Predispose Patients to Hepatocellular Carcinoma in the Absence of Cirrhosis? Grace Guzman, MD; Elizabeth M. Brunt, MD; Lydia M. Petrovic, MD; Gregorio Chejfec, MD;

More information

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies

More information

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,

More information

Negative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma

Negative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma Li et al. World Journal of Surgical Oncology (2015) 13:294 DOI 10.1186/s12957-015-0713-4 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Negative impact of low body mass index on liver cirrhosis

More information

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants Primary Sclerosing Cholangitis and Cholestatic liver diseases Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants I have nothing to disclose Educational Objectives What is PSC? Understand the cholestatic

More information

Hepatocellular carcinoma

Hepatocellular carcinoma Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular

More information

Status of hepatocellular carcinoma in Gulf region

Status of hepatocellular carcinoma in Gulf region Review Article Page 1 of 6 Status of hepatocellular carcinoma in Gulf region Kakil Ibrahim Rasul 1,2, Safaa H. Al-Azawi 1, Prem Chandra 3, Ghassan K. Abou-Alfa 4,5, Alexander Knuth 1 1 National Center

More information

Steatotic liver disease

Steatotic liver disease Steatotic liver disease Fatty liver disease Prof. Dr. ANNE HOORENS Non-Neoplastic Liver Pathology December 8th 2018 Working Group of Digestive Pathology Belgian Society of Pathology OUTLINE NAFLD = Non-Alcoholic

More information

Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화

Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화 Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화 Risk factors for HCC development (I) Environmental factors Infectious HBV HCV HDV Alimentary Alcohol Diet High

More information

THE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC)

THE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC) MEETING SUMMARY EASL 2017, AMSTERDAM, THE NETHERLANDS APRIL 19 TH TO 23 RD 2017 DR JEAN-CHARLES NAULT JEAN VERDIER HOSPITAL, BONDY, FRANCE THE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA

More information

Liver Cancer And Tumours

Liver Cancer And Tumours Liver Cancer And Tumours What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood from all parts of the body, cancer cells from elsewhere can

More information

Optimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC)

Optimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) XXVI SETH Congress- 30 November 2017 Optimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) Neil Mehta, MD University of California,

More information

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of

More information

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which

More information

Healthy Liver Cirrhosis

Healthy Liver Cirrhosis Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The

More information

Liver Transplant Pathology a general view

Liver Transplant Pathology a general view Liver Transplant Pathology a general view Dr S E Davies Addenbrooke s Hospital Cambridge University Hospitals NHS Trust ACP/BSG Meeting Leeds 2012 Liver transplantation When and where? Who and why? How?

More information

Hepatocellular Carcinoma: Transplantation, Resection or Ablation?

Hepatocellular Carcinoma: Transplantation, Resection or Ablation? Hepatocellular Carcinoma: Transplantation, Resection or Ablation? Roberto Gedaly MD Chief, Abdominal Transplantation Transplant Service Line University of Kentucky Nothing to disclose Disclosure Objective

More information

Non-Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the

More information

LIVER TRANSPLANTATION AS A TREATMENT OF HEPATOCELLULAR CARCINOMA

LIVER TRANSPLANTATION AS A TREATMENT OF HEPATOCELLULAR CARCINOMA ;t/-j) LIVER TRANSPLANTATION AS A TREATMENT OF HEPATOCELLULAR CARCINOMA D.H. Van Thiel, M.D., B. I. Carr, M.D., Ph.D., I. Yokoyama, M.D., S. Iwatsuki, M.D. and T.E. Starzl, M.D., Ph.D. From the Department

More information

Liver transplantation is the only hope for patients with terminal. Indication and Prognosis of Liver Transplantation. Abstract

Liver transplantation is the only hope for patients with terminal. Indication and Prognosis of Liver Transplantation. Abstract Indication and Prognosis of Liver Transplantation Jae Won Joh, M.D. Department of General Surgery Sungkyunkwan University School of Medicine Samsung Medical Center E mail: jwjoh@smc.samsung.co.kr Abstract

More information

Natural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry

Natural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry 2015;112:872 876 Natural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry PETER L. JERNIGAN, MD, KOFFI WIMA, MS, DENNIS J. HANSEMAN, PhD, RICHARD

More information

HCV care after cure. This program is supported by educational grants from

HCV care after cure. This program is supported by educational grants from HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico

More information

The Effect of Liver Transplantation on Autonomic Dysfunction in Patients with End-Stage Liver Disease

The Effect of Liver Transplantation on Autonomic Dysfunction in Patients with End-Stage Liver Disease LIVER TRANSPLANTATION 14:235-239, 2008 ORIGINAL ARTICLE The Effect of Liver Transplantation on Autonomic Dysfunction in Patients with End-Stage Liver Disease Elizabeth J. Carey, Manjushree Gautam, 3 Timothy

More information

Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?

Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? Original Article Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? R. F. Saidi 1 *, Y. Li 2, S. A. Shah 2, N. Jabbour 2 1 Division of Organ Transplantation, Department

More information

Liver Cancer. Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine

Liver Cancer. Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Liver Cancer Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Primary Liver Cancer Hepatocellular carcinoma (HCC) : > 80% Derived

More information

MRI for HCC surveillance and reporting: LI-RADS. Donald G. Mitchell, M.D. Thomas Jefferson University Philadelphia, PA

MRI for HCC surveillance and reporting: LI-RADS. Donald G. Mitchell, M.D. Thomas Jefferson University Philadelphia, PA MRI for HCC surveillance and reporting: LI-RADS Donald G. Mitchell, M.D. Thomas Jefferson University Philadelphia, PA Cirrhotic Nodules Regenerative Nodule Atypical Nodule Hyperplastic Nodule Dysplastic

More information

LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES

LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions

More information